BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (MARCH - APRIL 2018)

Efficacy and Safety of Alirocumab: Systematic Review of Randomized Controlled Trials

Rizwana Parveen1, Nouroz Sehar2 & Nidhi Bharal Agarwal3*

Introduction: Despite the availability of intensive statin therapy, some high risk patients do not achieve the recommended low-density lipoprotein cholesterol (LDL-C) level, while some are intolerant to statins. Therefore, alternative therapies are warranted with novel mechanisms. Alirocumab (ALI), is a newer lipid lowering agent that acts by inhibiting PCSK9, thus resulting in a decrease in circulating LDL-C levels. This systematic review of randomized clinical trials was performed to assess the efficacy and safety of ALI.. 

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.